Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Merck has agreed to license its CRISPR gene-editing technology to German biotech company Evotec.
Lawyers representing Italian medical devices company iVis Technologies have welcomed a decision of the European Patent Office to confirm the validity of one of the company’s patents, and are now pressing ahead with infringement claims against a German rival.
Pfizer UK has launched a new social media campaign urging people not to be “catfished” into buying counterfeit drugs.
African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.
The English High Court has sided with pharmaceutical company Vectura and Novartis-owned Sandoz in a passing off lawsuit brought by rival GSK.
An independent parliamentary report has today, September 27, revealed that the UK’s health ministry remains unsure whether the country’s health service can fully withstand the impact of a no-deal Brexit next month.
Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.
The European Parliament has said that the internal rules of the European Patent Office “must not undermine democratic political control of European patent law”.
UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.